<DOC>
	<DOCNO>NCT00188695</DOCNO>
	<brief_summary>The purpose study test whether new contrast agent call Combidex , contrast agent formulate ultra-small superparamagnetic iron oxide ( USPIO ) improve ability Magnetic Resonance Imaging ( MRI ) see lymph node pelvis . It might also help doctor tell whether cancer spread lymph node . It might allow radiotherapy deliver accurately .</brief_summary>
	<brief_title>Combidex USPIO - Ultra-Small Superparamagnetic Iron Oxide</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>histologically confirm endometrial , cervix , prostate ( cT1cT3 ) bladder cancer distant metastasis inform consent confirm prostate carcinoma PSA le equal 4 great 100 radical surgery prior cryosurgery prostate carcinoma , previous RT , hormonal manipulation chemotherapy biopsyproven lymph node involvement endometrium cervix carcinoma undergone recent pelvic surgery exclusion D &amp; C biopsy bladder carcinoma recent pelvic surgery exclusion TURBT previous concurrent cancer superficial basal squamous cell skin carcinoma unless diseasefree least 5 yrs contraindication MR image hip prosthesis major medical psychiatric illness patient know allergy dextran ironcontaining compound patient cirrhosis hemochromatosis patient receive another MR contrast within 2 hrs prior ferumoxtran10</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>